Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cullin 4A (CUL4A) is a scaffold protein that forms part of the Cullin-RING ubiquitin ligase (CRL4) complex, which is essential for the ubiquitination and subsequent degradation of various regulatory proteins involved in DNA replication, repair, and cell cycle progression (UniProt P39905). The 3' untranslated region (3'UTR) of the CUL4A mRNA serves as a critical regulatory hub, containing multiple binding sites for microRNAs (miRNAs) such as miR-124, miR-194, and miR-494, which normally suppress CUL4A expression (PubMed: 25605130, 26823714, 25193394). In many cancers, CUL4A is overexpressed due to the downregulation of these inhibitory miRNAs or genomic amplification, leading to the accelerated degradation of tumor suppressors like p53 and p21 (PubMed: 23835303). Consequently, the CUL4A mRNA 3'UTR is an attractive therapeutic target for RNA-based interventions, including miRNA mimics or antisense oligonucleotides, designed to restore post-transcriptional silencing and reduce oncogenic CUL4A levels. Modulating this region has shown potential in preclinical models to inhibit tumor cell proliferation, invasion, and epithelial-mesenchymal transition. This target represents a specific site for precision medicine approaches aimed at correcting the dysregulated protein degradation pathways characteristic of aggressive malignancies.
Binding of microRNA mimics or antisense oligonucleotides to the 3'UTR sequence induces mRNA degradation or inhibits translation, thereby reducing the cellular levels of the oncogenic CUL4A protein.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cullin 4A messenger RNA 3' untranslated region (CUL4A mRNA 3'UTR) (CUL4A mRNA 3'UTR).